Storia in 2 fonti

Why Is Regeneron Stock Sinking Monday? - Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.

Raccontata da

biopharmadive.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mesi fa

Why Is Regeneron Stock Sinking Monday? - Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.

originale

biopharmadive.com1 mesi fa

Regeneron immunotherapy combo comes up short in melanoma trial

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

Leggi questa versione → originale

Timeline cronologica

lunedì 18 maggio 2026·biopharmadive.com
Regeneron immunotherapy combo comes up short in melanoma trial
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out…
lunedì 18 maggio 2026·benzinga.com
Why Is Regeneron Stock Sinking Monday? - Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.